Clearside Biomedical Data Featured in Six Presentations At Association for Research in Vision and Ophthalmology 2025 Meeting

Published: 2025-05-09 07:05:00 ET CLSD

Published on 05/09/2025 at 07:05, updated on 05/09/2025 at 08:05

Clearside Biomedical, Inc. announced that six presentations related to the Company's lead program, CLS-AX (axitinib injectable suspension), and suprachoroidal drug delivery platform were featured at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting. Preclinical and clinical trial results demonstrate that CLS-AX has the potential to be a safe and long-acting therapy for wet AMD given its durability, intrinsic high potency, pan-VEGF inhibition, and proven ability to re-dose. Presentation Key Highlights: Positive data presented from the CLS-AX Phase 2b ODYSSEY trial, which achieved the primary outcome of maintaining stable best corrected visual acuity (BCVA) with repeat dosing while meaningfully reducing the frequency of injections.

Clearside's Phase 3 trial design to feature the flexible dosing of an anti-VEGF biologic with the duration of a pan-VEGF receptor tyrosine kinase inhibitor (TKI). A decade-long literature review of suprachoroidal delivery across preclinical studies and clinical trials provides key evidence to support the suprachoroidal platform as an opportunity to expand the standard of care in the treatment of macular diseases. Presentation Details: Top Line Results from ODYSSEY: A Phase 2b Study of Suprachoroidally Administered CLS-AX in Participants with Neovascular Age-related Macular Degeneration.